In the last years, an increasing number of apparently
|
|
- Brian Francis
- 5 years ago
- Views:
Transcription
1 Evidence of Serious Graft Damage Induced by De Novo Hepatitis B Virus After Liver Transplantation Roberto Segovia, * Alberto Sánchez-Fueyo, * Antoni Rimola, * Luis Grande, Miquel Bruguera, * Josep Costa, Carolina Soguero, * and Juan Uriz * De novo hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT) is commonly believed to be a relatively benign condition, in contrast to post-olt infection recurrence, considered a very aggressive complication. We reviewed the charts of 569 non HBV-related OLTs performed at our institution and identified 19 patients (3%) with de novo HBV infection (appearance of hepatitis B surface antigen [HBsAg] after OLT). After a median follow-up of 25 months beyond the detection of HBsAg, 12 patients (63%) had developed serious HBVrelated graft damage (cirrhosis in 6 patients, bridging chronic hepatitis in 4 patients, and fulminant hepatitis in 2 patients); 7 patients (37%) had lost their grafts; and 4 patients (21%) had died. All graft losses and deaths were related to de novo HBV infection. Similar rates of severe graft damage (62%), graft loss (38%), and death (33%) related to HBV infection were found in a concomitant series of 21 patients with recurrent HBV infection after OLT. Responses to antiviral therapy (interferon or lamivudine) were also similar in the 2 groups of patients. In 12 patients with de novo HBV infection, evidence of past HBV infection (positive serum antibody to hepatitis B core antigen and/or serum or liver tissue ) were detected in the donor (7 patients) or recipient (5 patients). No differences were observed in the clinical course after stratification according to the attributed origin of de novo HBV infection. We conclude that de novo HBV infection after OLT is associated with high rates of morbidity and mortality, similar to those described for post-olt HBV infection recurrence. (Liver Transpl 2001;7: ) In the last years, an increasing number of apparently primary hepatitis B virus (HBV) infections after orthotopic liver transplantation (OLT) has been observed. These so-called de novo HBV infections have been reported to occur in 1% to 3% of liver transplant recipients without a known history of HBV infection. 1-4 However, although some patients may have From the *Liver Unit and the Departments of Surgery and Microbiology, Hospital Clinic, Institut D Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain. Support in part by a grant from Fundación Pedro Pons (A.S-F.) and a grant from Fundació Clínic (C.S.). Address reprint requests to Antoni Rimola, MD, Liver Unit, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain. Telephone: ; FAX: ; rimola@medicina.ub.es Copyright 2001 by the American Association for the Study of Liver Diseases /01/ $35.00/0 doi: /jlts true primary infections acquired through parenteral exposure to blood products or risky lifestyle practices, most cases appear to be caused by reactivation of latent virus, either from recipient extrahepatic sources 2,5 or, more frequently reported, from the liver graft itself. 6,7 The use of allografts from donors with serum immunoglobulin G (IgG) antibodies to hepatitis B core antigen (anti-hbc), usually considered a marker of past exposure to HBV, has been associated with de novo HBV infection in 50% to 93% of the recipients At variance with the poor prognosis of HBV infection recurrence in patients who undergo transplantation for HBV-related liver diseases, most studies have reported a comparatively benign course of de novo post-olt HBV infection, with very slow progression to severe graft damage and rarely leading to graft loss. 1,3,7,11 However, these findings have not been universal; recently, Crespo et al 12 reported a series of 6 patients with de novo HBV infection after OLT, 2 of whom lost their grafts because of HBV-induced fulminant hepatitis. A clear understanding of the course of these infections is crucial because it may have great impact on the use of anti-hbc positive liver donors, which constitute 5% of the donors in the United States 6,10 and approximately 12% of the donors in Spain. 13 The aim of the present study is to evaluate the natural history of de novo HBV infection after OLT in a single institution. Patients and Methods Patients From June 1988 to August 1999 at the Hospital Clinic of Barcelona, Spain, 703 OLTs were performed in 636 adult patients. Fifty-eight grafts were lost during the first postoperative month, and 645 grafts survived longer. Seventy-six of these 645 OLTs were performed in patients with HBV-related liver diseases (cirrhosis or fulminant hepatitis), defined by the positivity of serum hepatitis B surface antigen (HBsAg) before the procedure, whereas in the remaining 569 patients, OLT was performed for non HBV-related diseases (pre- OLT HBsAg negative). The development of de novo HBV infection was therefore studied in this group of 569 liver transplant recipients. Induction immunosuppression consisted of cyclosporine A, prednisone, and azathioprine in most patients, whereas 106 Liver Transplantation, Vol 7, No 2 (February), 2001: pp
2 De Novo Hepatitis B in Liver Transplantation 107 Table 1. Characteristics of Patients With De Novo HBV After OLT Sex (men/women) 12/7 Age* (yr) 45 (20-60) OLT indication (no. of patients) Alcoholic cirrhosis 7 HCV-induced cirrhosis 5 Other 7 Immunosuppression at time of HBV infection (no. of patients) CsA monotherapy 2 CsA prednisone 12 FK monotherapy 4 FK prednisone 1 HBsAg detection after OLT* (mo) 9 (4-81) Follow-up after HBV infection* (mo) 25 (0-108) Abbreviations: CsA, cyclosporine A; FK, tacrolimus. *Values expressed as median (range). Four patients with cirrhosis also had hepatocellular carcinoma. some patients were initially treated with tacrolimus and prednisone. All patients were followed up at the Hospital Clinic outpatient clinic, and serum HBsAg levels were determined at month 3 after OLT and subsequently every 6 months and when clinically indicated. Tests for, hepatitis Be antigen (HBeAg), antibody to HBeAg (anti-hbe) and antibody to hepatitis D virus (anti-hdv) were also performed periodically in patients with HBsAg seroconversion. Percutaneous liver biopsies were performed when clinically indicated during the first months and routinely at 12 months after OLT and every 1 to 2 years thereafter in those patients who developed liver disease. Patients with HBV infection after OLT also underwent a liver biopsy when HBsAg was first detected postoperatively. Nineteen of the 569 transplant recipients (3%) who were HBsAg negative before OLT presented post-olt with de novo HBV infection, defined by the detection of HBsAg after OLT. HBV infection recurrence, defined as the reappearance of HBsAg after OLT, occurred in 21 of the 76 HBsAg-positive liver transplant recipients (28%). Clinical data from the 19 patients with de novo HBV infection and the 21 patients with HBV infection recurrence were retrospectively collected and compared. Virological Studies HBsAg, antibody to HBsAg (anti-hbs), HBeAg, anti- HBe, IgG anti-hbc, and anti-hdv were determined by enzyme-linked immunoassay using commercial kits. HBV DNA was detected by a spot hybridization technique until 1991, and thereafter by single-round polymerase chain reaction (PCR), as previously described. 14 In 16 patients with de novo HBV infection in whom frozen ( 70 C) pre-olt sera from transplant recipients were available, heminested PCR was performed to detect trace amounts of, as previously described. 15 Sensitivity of this technique has been estimated to be 1 copy/ml. The presence of was also tested in paraffin-embedded liver biopsy specimens from the graft in 16 cases (biopsy obtained at reperfusion) and the explanted recipient liver in 18 cases. Extraction and amplification were performed as previously described. 16,17 All donors were HBsAg negative. Donor serum anti-hbc has been routinely determined at our institution since Since then, serum anti-hbc has been found positive in 9% of organ donors. Liver Histological Examination Liver biopsy specimens were reevaluated by a single pathologist (M.B.) blinded to the clinical diagnosis. Each liver specimen was assigned to 1 of the following diagnoses: acute hepatitis, submassive or massive hepatic necrosis, chronic hepatitis (mild, moderate, and severe, including those cases with bridging fibrosis), cirrhosis, and fibrosing cholestatic hepatitis. 18,19 Statistical Analysis Results are expressed as median and range. Comparison of quantitative data was performed by nonparametric Mann Whitney test. Qualitative data were compared by using chisquared test. Survival curves were generated by the Kaplan- Table 2. Characteristics of Patients With HBV Recurrence After OLT Sex (men/women) 18/3 Age* (yr) 42 (19-63) OLT indication (no. of patients) HBV-induced fulminant hepatitis 7 HBV-related cirrhosis 14 HDV coinfection at time of OLT (no. of patients) 3 HCV coinfection at time of OLT (no. of patients) 2 Long-term HBIG prophylaxis (no. of patients) 7 Immunosuppression at time of recurrence (no. of patients) CsA monotherapy 2 CsA prednisone 18 FK prednisone 1 Time of HBsAg detection after OLT* (mo) 4 (1-11) Follow-up after HBV recurrence* (mo) 40 (3-117) Abbreviations: CsA, cyclosporine A; FK, tacrolimus; HBIG, hepatitis B immune globulin. *Values expressed as median (range). Three patients with cirrhosis also had hepatocellular carcinoma.
3 108 Segovia et al Meier method to estimate survival of both allografts and recipients in the 2 groups of patients studied (de novo post- OLT HBV infection and HBV infection recurrence). Logrank test was used to compare the curves. P less than.05 is considered statistically significant. Results Patient Characteristics Clinical characteristics of the patients with de novo HBV infection and those with HBV infection recurrence are listed in Tables 1 and 2, respectively. In the 19 patients with de novo HBV infection, HBsAg was detected a median of 9 months (range, 4 to 81 months) after OLT, and patients were followed up for a median of 25 months (range, 0 to 108 months) after HBV infection. The median peak serum transaminase levels were 67 U/L (range, 19 to 2,346 U/L) for aspartate aminotransferase and 136 U/L (range, 33 to 2,819 U/L) for alanine aminotransferase. In only 5 cases did serum transaminase values remain less than 2 times the upper level of normal (40 U/L). Virological data and clinical course of the 19 cases are listed in Table 3. At the end of follow-up, 12 patients (63%) had serious HBV-related graft damage (severe chronic hepatitis, cirrhosis, or massive or submassive necrosis). It is noteworthy that 2 patients presented with fulminant hepatitis and 1 other patient experienced a severe reactivation of chronic hepatitis, all of whom subsequently died. No cases of fibrosing cholestatic hepatitis were observed. As listed in Table 3, there were 7 graft losses (37%) and 4 deaths (21%). In 4 patients, graft loss was directly related to de novo HBV infection, and in the remaining 3 patients, the grafts were lost because of a combination of both severe HBVrelated graft damage and other causes (hepatitis C virus [HCV] infection recurrence and biliary strictures). All 4 deaths were directly related to HBV infection. Interferon was administered to 3 patients, with negativization in all patients and seroconversion to anti- HBs positive status in 2 patients. Lamivudine is currently being administered to 5 other patients, with negativization but persistence of HBsAg in all patients. Spontaneous seroconversion to anti-hbs positive status was observed in only 1 patient. In the 21 patients with HBV infection recurrence, the median time between OLT and HBsAg reappearance was 4 months (range, 1 to 11 months), which was Table 3. Course of Patients With De Novo HBV After OLT Patient No. OLT Indication HBeAg at HBV DNA at Time of After OLT (mo) Follow-Up After (mo) Treatment (mo of therapy) Associated Graft Disorders Histology (end of follow-up) Current Status 1 Alcoholic cirrhosis ND ND 5 0 Massive necrosis Dead 2 Alcoholic cirrhosis ND Alive 3 HCV cirrhosis Submassive necrosis Dead 4 HCV cirrhosis HCV recurrence MCH Alive 5 HCV cirrhosis 6 57 IFN (24) HCV recurrence Cirrhosis Re-OLT/alive 6 Re-OLT 8 64 Cirrhosis Re-OLT/alive 7 HCV cirrhosis HCV recurrence MCH Alive 8 Type 1 primary hyperoxaluria IFN (12) SCH Alive 9 Primary sclerosing cholangitis IFN (16) Cirrhosis Alive 10 Alcoholic cirrhosis 4 52 Cirrhosis Dead 11 Alcoholic cirrhosis 7 48 LMV (11) SCH Alive 12 Alcoholic cirrhosis SCH Alive 13 Biliary strictures (re-olt) LMV (9) Biliary strictures Cirrhosis Re-OLT/alive 14 Alcoholic cirrhosis 4 28 ND Alive 15 HCV cirrhosis 8 21 LMV (8) HCV recurrence Cirrhosis Alive 16 Alcoholic cirrhosis 6 16 LMV (9) MCH Alive 17 Autoimmune hepatitis 10 9 LMV (5) Biliary strictures ND Alive 18 Caroli s disease 14 9 ND Alive 19 Cryptogenic cirrhosis 4 1 Submassive necrosis Dead Abbreviations: ND, not done; IFN, interferon; LMV, lamivudine; MCH, moderate chronic hepatitis; SCH, severe chronic hepatitis. *All deaths and re-olts were caused by HBV-related graft damage. Graft disorders other than HBV infection contributed to death or re-olt in patients 5 and 13 (HCV recurrence and biliary strictures, respectively). Chronic hepatitis with a final reactivation leading to submassive necrosis. Re-OLT for graft failure caused by cirrhosis of undetermined origin (negative serum HBsAg and, but positive anti-hbc IgG and liver tissue ). In patients 6 and 17, infection was attributed to a precore mutant on the basis of persistent HBeAg negativity in the presence of positivity for and anti-hbeag.
4 De Novo Hepatitis B in Liver Transplantation 109 significantly shorter than in the de novo HBV group (P.045). Virological characteristics and courses of these patients are listed in Table 4. After a median follow-up of 40 months (range, 3 to 117 months), 13 of 21 patients (62%) had severe HBV-related graft damage, a rate similar to that observed in the group with de novo HBV infection. Fourteen patients (67%) lost their grafts, and 13 patients (62%) died. As listed in Table 4, in 8 patients (38%), HBV infection recurrence had a direct (4 patients) or contributory role (4 patients) in graft loss, whereas the remaining 6 graft losses were from causes other than HBV infection. Seven deaths (33%) were either directly related to HBV infection recurrence (3 deaths) or caused by a combination of HBV infection recurrence and other graft lesions (4 deaths). Rates of graft loss and patient mortality from HBV infection recurrence did not significantly differ from those in the group with de novo HBV infection (37% v 38%; 21% v 33%, respectively). Four patients with HBV infection recurrence underwent treatment with interferon, and was cleared during treatment in 3 patients, although only 1 patient seroconverted to anti-hbs positive status. Three other patients are currently undergoing treatment with lamivudine, and all have become negative for, although HBsAg is still present. Figure 1 shows cumulative graft and patient survival in the groups with de novo and recurrent HBV infection. Although a tendency toward poorer outcome was observed in the group with HBV recurrence, the difference is not statistically significant. Origin of De Novo HBV After OLT As listed in detail in Table 5, evidence of past HBV infection was found in either the donor or recipient in 12 cases of de novo HBV infection, although pre-olt serum anti-hbc was the only positive marker found in 2 transplant recipients. In 2 patients (no. 12 and 19), HBV infection could not be attributed to any potential origin after complete studies were performed. No relationship between the possible origin of de novo HBV infection and the clinical course of patients was observed. Discussion Since the initial description in 1992 of de novo HBV infection in patients who underwent OLT for non Table 4. Course of Patients With HBV Recurrence After OLT Patient No. OLT Indication HBeAg at Recurrence HBV DNA at Recurrence Time of Recurrence After OLT (mo) Follow-Up After Recurrence (mo) Treatment (mo of therapy) Associated Graft Disorders Histology (end of follow-up) Current Status 1 Cirrhosis 6 3 Submassive necrosis Dead* 2 Cirrhosis 1 12 SCH Dead 3 Fulminant hepatitis 1 96 Cirrhosis Re-OLT/dead* 4 Cirrhosis 4 31 Cirrhosis Dead* 5 Cirrhosis IFN (15) Mild CH Alive 6 Fulminant hepatitis Chronic rejection MCH Dead 7 Fulminant hepatitis Cirrhosis Alive 8 Fulminant hepatitis 2 56 Chronic rejection FCH Dead* 9 Cirrhosis 3 61 IFN (4) HCV recurrence Cirrhosis Dead* 10 Cirrhosis IFN (12) Cirrhosis Alive 11 Cirrhosis 5 13 Caval vein stenosis Cirrhosis Dead* 12 Cirrhosis 4 99 IFN (38) Cirrhosis Alive 13 Cirrhosis 4 92 Biliary strictures MCH Re-OLT/alive 14 Fulminant hepatitis Chronic rejection Cirrhosis Dead* 15 Fulminant hepatitis 10 9 Chronic rejection Acute hepatitis Dead 16 Fulminant hepatitis 1 26 MCH Dead 17 Cirrhosis 5 11 Minimal changes Dead 18 Cirrhosis 1 11 Cirrhosis Dead* 19 Cirrhosis 9 40 LMV (16) Cirrhosis Alive 20 Cirrhosis 7 16 LMV (12) MCH Alive 21 Cirrhosis 6 9 LMV (6) MCH Alive Abbreviations: IFN, interferon; LMV, lamivudine; MCH, moderate chronic hepatitis; SCH, severe chronic hepatitis; FCH, fibrosing cholestatic hepatitis; CH, chronic hepatitis. *Deaths and re-olts caused by HBV-related graft damage (other graft disorders contributed to death or re-olt in patients 8, 9, 11, and 14). Patients 6, 10, 19, 20, and 21 were considered to be infected by precore mutants on the basis of persistent HBeAg negativity in the presence of positive for and anti-hbeag.
5 110 Segovia et al Figure 1. Graft and patient cumulative survival after OLT in de novo HBV infection (continuous line) and HBV infection recurrence (broken line). HBV-related liver diseases, 20 it has been generally assumed that this entity is mostly associated with a benign clinical course. This initial impression was supported by several studies. Douglas et al 1 reported progression to severe liver disease in only 1 of 5 patients. Fabia et al 3 found significant serum transaminase level elevations in only 2 of 14 patients after 28 months of follow-up, and Chazouillères et al 5 reported a series of 20 patients in which 10 patients developed chronic hepatitis and only 1 patient required re-olt for HBV-induced graft failure. Conversely, Wachs et al, 9 alerted to the possibility of severe consequences of de novo HBV infection in OLT, published a short series of 3 patients, in which 1 patient developed active chronic hepatitis and 2 patients developed cirrhosis after HBV infection. Similarly, Roche et al 2 reported 20 patients with de novo HBV infection; 5 patients developed cirrhosis, resulting in graft loss in 2 patients, and 9 patients evolved to chronic active hepatitis. In addition, 1 Spanish institution recently reported its experience showing a particularly severe clinical course of de novo HBV infection that included the first reported cases of fulminant hepatitis. 12 In our series, 19 patients developed de novo HBV Table 5. Pre-OLT Markers of HBV in Donors and Recipients in 19 Cases of De Novo HBV After OLT Patient No. Anti-HBc Donor Liver Tissue Anti-HBc Recipient Liver Tissue 1 ND ND ND ND ND 2 ND ND ND ND 3 ND ND ND ND 4 ND ND ND 5 ND ND 6 ND ND 7 ND ND ND 8 ND ND 9 ND ND 10 ND ND 11 ND ND ND ND Abbreviations: ND, not determined; Anti-HBc, antibody to HBcAg.
6 De Novo Hepatitis B in Liver Transplantation 111 infection post-olt, representing an incidence of 3%. In this group of patients, severe graft damage (cirrhosis, chronic hepatitis with bridging fibrosis, or massive or submassive liver necrosis) was observed in 63% of the patients. This incidence was almost identical to the incidence of severe graft damage observed in patients with recurrent HBV infection (62%), who constitute a population traditionally associated with a very poor prognosis. 19 Although some patients with de novo HBV infection also had concomitant disorders that could contribute to graft injury (i.e., HCV infection recurrence or biliary strictures), the role of these conditions in the graft damage seems modest because they were present in only 3 of the 12 patients with severe HBV-related graft lesions (Table 3). In the group with HBV infection recurrence, associated serious graft disorders were present in 5 of 13 patients with severe HBV-related graft damage (Table 4). Actuarial probabilities of graft and patient survival in the 2 groups were not statistically different, although a tendency toward a worse outcome was observed in patients with HBV infection recurrence (Fig. 1). Nevertheless, when only graft loss and death related to HBV infection (as either the only cause or a major contributory cause) are considered, patients with de novo HBV infection and patients with HBV infection recurrence did not significantly differ with regard to these events: graft loss rates were 37% versus 38% and patient mortality rates were 21% versus 33% in the de novo and recurrent HBV infection groups, respectively. Interestingly, 2 patients with de novo HBV infection developed fulminant hepatic failure, a phenomenon previously described by Crespo et al, 12 and a third patient (with chronic hepatitis) had a severe reactivation that caused submassive hepatic necrosis. We did not observe fibrosing cholestatic hepatitis, although its occurrence as a consequence of de novo HBV infections has been previously described. 7 Only 1 patient spontaneously seroconverted to anti-hbs positive status, reflecting the extremely high propensity to chronicity of HBV infection in the OLT setting. 21 Eight patients with de novo HBV infection were administered either interferon or lamivudine. Despite the high antiviral efficacy of these therapies (HBV DNA became negative in all 8 patients), their impact on the graft damage is difficult to ascertain in the present series because these products were administered in most cases when severe graft injury had already developed. The origin of de novo HBV infection after OLT has often been attributed to the presence of trace amounts of latent HBV in the graft, with the presence of serum IgG anti-hbc in the donor considered its best marker. 3,6,9 However, as shown by previous studies 2,5,12 and our own data, the donor origin of HBV infection cannot always be found. An alternative source of HBV infection is the presence of cryptic hepatic or extrahepatic HBV infection in the recipient (defined as the detection of by PCR, either in serum or liver tissue, in the absence of other HBV serological markers). 5 In our study, 3 cases of de novo HBV infection might have been attributed to this source. As the relationship between cryptic HBV infection and post- OLT HBV hepatitis becomes more widely recognized, these cases will probably have to be reclassified as recurrent infections. In 2 other transplant recipients, serum anti-hbc was positive before OLT as the only serological marker, although the role of this condition in the pathogenesis of de novo HBV infection seems less clear. However, 2 of our patients developed HBV infection 4 and 11 months after OLT in the absence of either donor serum anti-hbc or recipient cryptic HBV infection, highlighting the difficulties in identifying all possible infective sources. Taking into account that serum anti-hbc tests are not routinely performed in blood donors at our institution, we believe this could be a potential source of transmission. A clear understanding of the potential severity of de novo HBV infection is extremely relevant to address the question of whether anti-hbc positive donors should be used. This is probably not a major issue in areas of low anti-hbc serum prevalence, such as the United States ( 3.8% to 5.3% of donors), 6,22 but it is becoming increasingly important in countries of intermediate or high prevalence, such as Spain and Japan (12% and 27%, respectively). 7,13 To date, there are no published data on the use of pharmacological prophylaxis with either hepatitis B immunoglobulin or lamivudine to reduce the risk for HBV transmission in patients receiving serum anti-hbc positive grafts. Both strategies, along with the diversion of anti-hbc positive grafts to serum anti-hbs positive recipients, appear to be sensible. 4 In summary, we believe that de novo HBV infection after OLT is not a benign event, but is associated with a high rate of morbidity and mortality. Efforts must be made to properly identify all potential transmission paths, and when this can be accomplished, empirical prophylactic regimens are probably indicated. References 1. Douglas D, Rakela J, Wright T, Krom R, Wiesner R. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997;3:
7 112 Segovia et al 2. Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997;26: Fabia R, Levy M, Crippin J, Tillery W, Netto G, Aguanno J, et al. De novo hepatitis B infection after liver transplantation: Source of disease, incidence, and impact. Liver Transpl Surg 1998;4: Pruett T. Editorial response: De novo HBV infections after liver transplantation. Liver Transpl Surg 1998;4: Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. Occult hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343: Dickson R, Everhart J, Lake J, Wei Y, Seaberg E, Wiesner R, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997;113: Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living-related liver transplant. Transplantation 1998;65: Caldwell S. Editorial response: Hard times and imperfect organs. Liver Transpl Surg 1997;3: Wachs M, Amend W, Ascher N, Bretan P, Emond J, Lake J, et al. The risk of transmission of hepatitis B from HBsAg( ), HBcAb( ), HBIgM( ) organ donors. Transplantation 1995; 59: Dodson S, Rakela J, Bonham C, Geller D, Fung J, Starzl T. The use of hepatic allografts from anti-hbc positive donors in anti- HBs positive recipients [abstract]. Hepatology 1999;30:246A. 11. Cavallari A, De Raffele E, Bellusci R, Miniero R, Vivarelli M, Galli S, et al. De novo hepatitis B and C viral infection after liver transplantation. World J Surg 1997;21: Crespo J, Fabrega E, Casafont F, Rivero M, de las Heras G, de la Peña J, et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999;5: Prieto M, Gomez M, Garcia A, Berenguer M, Rayon J, Cordoba J, et al. Low rate of post-transplantation de novo hepatitis B virus infection from anti-hbc positive donors: Association with anti- HBc/anti-HBs status in the recipient [abstract]. Hepatology 1999;30:242A. 14. Costa J, López-Labrador F, Sánchez-Tapias J, Mas A, Vilella A, Olmedo E, et al. Microwave treatment of serum facilitates detection of hepatitis B virus DNA by the polymerase chain reaction. Results of a study in anti-hbe positive chronic hepatitis B. J Hepatol 1995;22: Lindh M, Andersson AS, Gusdal AK. Genotypes, nt1858 variants, and geographic origin of hepatitis B virus Large scale analysis using a new genotyping method. J Infect Dis 1997;175: Soguero C, Ribalta T, Campo E, Sánchez-Tapias J, Sáiz J, Bruguera M. Detection of hepatitis C virus (HCV) RNA in more than 20-year-old archival liver tissue. Lab Invest 1999;79: Koike K, Kobayashi M, Gondo M, Hayashi I, Osuga T, Takada S. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998;54: Batts K, Ludwig J. Chronic hepatitis: An update on terminology and reporting. Am J Surg Pathol 1995;19: Davies S, Portmann B, O Grady J, Aldis P, Chaggar K, Alexander G, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13: Douglas D, Rakela J, Taswell H, Mamish D, Wright T, Krom R, et al. Transmission of hepatitis B virus infection from orthotopic donor livers [abstract]. Hepatology 1992;16:49A. 21. Di Bisceglie A, Hoofnagle J. Chronic hepatitis B. In: Zakim D, Boyer T (eds). Hepatology: A textbook of liver disease (ed 3). Philadelphia: Saunders, 1996: Dodson S, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997;64:
De novo hepatitis B infection acquired during liver transplantation
Q JMed 2001; 94:271±275 De novo hepatitis B infection acquired during liver transplantation P.J. GOW and D.J. MUTIMER From the Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Birmingham, UK Received
More informationL iver transplantation is the major treatment for patients
95 LIVER AND BILIARY DISEASE Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-hbc positive donors A M Roque-Afonso, C Feray, D Samuel, D Simoneau,
More informationPATIENTS AND METHODS. Patients. Between July 1990 and April 1996, 36 HBsAg-positive recipients were submitted to liver transplantation at the Hospital
Hepatitis B Immunoglobulin Discontinuation Followed by Hepatitis B Virus Vaccination: A New Strategy in the Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation ALBERTO SÁNCHEZ-FUEYO,
More informationAntibody to Hepatitis B Core Antigen Positive Grafts: Not Perfect but No Longer Marginal
LIVER TRANSPLANTATION 15:1164-1168, 2009 EDITORIAL Antibody to Hepatitis B Core Antigen Positive Grafts: Not Perfect but No Longer Marginal Martín Prieto Hepatogastroenterology Service, Hospital Universitario
More informationHepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses
Hepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses Mario G. Pessoa,*00 Norah A. Terrault,*00 Linda D. Ferrell, Jill Detmer, Janice Kolberg, Mark L. Collins, Maurene Viele,
More informationPAPER. Use of Hepatitis B Core Antibody Positive Donors in Orthotopic Liver Transplantation. transplantation (OLT) experience
PAPER Use of Hepatitis B Core Antibody Positive Donors in Orthotopic Liver Transplantation David Holt, MD; Ryan Thomas, BS; David Van Thiel, MD; John J. Brems, MD Hypothesis: Hepatic allografts from donors
More informationDonor organ shortages occasionally mandate the
Active Immunization Against De Novo Hepatitis B Virus Infection in Pediatric Patients After Liver Transplantation Seong-Hwan Chang, 1 Kyung-Suk Suh, 1 Nam-Joon Yi, 1 Seok Ho Choi, 1 Hoan Jong Lee, 2 Jeong
More informationDe novo hepatitis B virus infection developing after liver transplantation using a graft positive for hepatitis B core antibody
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/10.4174/astr.2015.89.3.145 Annals of Surgical Treatment and Research De novo hepatitis B virus infection developing after liver transplantation
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationSpontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report
Hara et al. Surgical Case Reports (2016) 2:118 DOI 10.1186/s40792-016-0246-2 CASE REPORT Open Access Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationSurvival After Orthotopic Liver Transplantation: The Impact of Antibody Against Hepatitis B Core Antigen in the Donor
LIVER TRANSPLANTATION 15:1343-1350, 2009 ORIGINAL ARTICLE Survival After Orthotopic Liver Transplantation: The Impact of Antibody Against Hepatitis B Core Antigen in the Donor Lei Yu, 1-3 Thomas Koepsell,
More informationLeading article. Hepatitis C and liver transplantation
Gut 1999;45:159 163 159 Leading article Hepatitis C and liver transplantation Introduction Cirrhosis secondary to hepatitis C virus (HCV) infection, alone or in combination with alcohol, is the principal
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationE nd stage liver disease due to hepatitis C virus infection
248 LIVER DISEASE Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C M Wali, R F Harrison, P J Gow, D Mutimer... Gut 2002;51:248 252 See end of article for
More informationORIGINAL ARTICLE. Robert Perrillo Hepatology Division, Baylor University Medical Center, Dallas, TX
LIVER TRANSPLANTATION 15:223-232, 2009 ORIGINAL ARTICLE Hepatitis B Virus Prevention Strategies for Antibody to Hepatitis B Core Antigen Positive Liver Donation: A Survey of North American, European, and
More informationNatural History of Clinically Compensated Hepatitis C Virus Related Graft Cirrhosis After Liver Transplantation
Natural History of Clinically Compensated Hepatitis C Virus Related Graft Cirrhosis After Liver Transplantation MARINA BERENGUER, 1 MARTÍN PRIETO, 1 JOSÉ M. RAYÓN, 2 JULIO MORA, 1 MIGUEL PASTOR, 1 VICENTE
More informationCurrently, the leading indication for liver transplantation
ORIGINAL ARTICLES Severe Recurrent Hepatitis C After Liver Retransplantation for Hepatitis C Virus Related Graft Cirrhosis Marina Berenguer, * Martín Prieto, * Antonio Palau, * José M. Rayón, Domingo Carrasco,
More informationTrapianto di fegato e organi solidi. Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine
Trapianto di fegato e organi solidi Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine Case 1 55-yr old white woman Alcoholic cirrhosis (CTP score 11, MELD 24, status UNOS
More informationMore than 350 million people worldwide are
Double-Dose Accelerated Hepatitis B Vaccine in Patients With End-Stage Liver Disease Mehmet Arslan, * Russell H. Wiesner, * Corey Sievers, * Kathleen Egan, and Nizar N. Zein * The aims of this study are
More informationOriginal article De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation
Antiviral Therapy 11; 1:9 8 (doi: 1.381/IMP11) Original article De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation Yoshihide Ueda
More informationHepatitis A-E Viruses. Dr Nemes Zsuzsanna
Hepatitis A-E Viruses Dr Nemes Zsuzsanna Viral Hepatitis - Historical Perspectives Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D C Parenterally transmitted HGV, TTV, SEN, other
More informationAlla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )
Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationEffect of Calcineurin Inhibitors on Survival and Histologic Disease Severity in HCV-Infected Liver Transplant Recipients
LIVER TRANSPLANTATION 12:762-767, 2006 ORIGINAL ARTICLE Effect of Calcineurin Inhibitors on Survival and Histologic Disease Severity in HCV-Infected Liver Transplant Recipients Marina Berenguer, 1 Victoria
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection
Title page HBV Core and Core-Related Antigen Quantitation in Chinese Patients with Chronic Hepatitis B Genotype B and C Virus Infection Short Title: Quantitation of HBc and HBcrAg in Chinese patients Akinori
More informationCirrhosis secondary to hepatitis C virus (HCV) infection
The Use of Hepatitis C Viral RNA Levels in Liver Tissue to Distinguish Rejection From Recurrent Hepatitis C Michelle J. Gottschlich, * Kay L. Aardema, Eileen M. Burd, Raouf E. Nakhleh, Kimberly A. Brown,
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationTrapianto di fegato e organi solidi. Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine
Trapianto di fegato e organi solidi Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine Case 2 53-yr old white man PSC (CTP score 10, MELD 23, status UNOS 2B) HBsAb-, HBcAb-
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationViral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP
Viral Hepatitis Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP Viral hepatitis Viral hepatitis must be considered in any patient presenting with hepatitis on LFTs (high
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationRECURRENT HEPATITIS C CIRRHOSIS AFTER LIVER TRANSPLANTATION: A NATURAL HISTORY STUDY
RECURRENT HEPATITIS C CIRRHOSIS AFTER LIVER TRANSPLANTATION: A NATURAL HISTORY STUDY By VIRGINIA C. CLARK A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationRecurrence of hepatitis C virus (HCV) after orthotopic. Poor Survival After Liver Retransplantation: Is Hepatitis C to Blame?
RAPID COMMUNICATION Poor Survival After Liver Retransplantation: Is Hepatitis C to Blame? Kymberly D.S. Watt, Elizabeth R. Lyden, and Timothy M. McCashland Data from 1990 to 1996 suggest that the prevalence
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationAnti-hepatitis C virus core IgM antibodies correlate with hepatitis C recurrence and its severity in liver transplant patients
698 Hepatology Unit, Hôtel-Dieu, Lyon 6988, France S N Si Ahmed Department of Liver Transplantation, Croix-Rousse, Lyon 697, France M Adham C Ducerf J Baulieux Laboratoire d Hygiène, Faculté Rockefeller,
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationThe ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013
The ABC s (and D & E s) of the Viral Hepatitides Part 2 Thomas Novicki PhD DABMM Clinical Microbiologist Division of Laboratory Medicine novicki.thomas@marshfieldclinic.org Objectives 2 1. Explain the
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationHBV : Structure. HBx protein Transcription activator
Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase
More informationInfective hepatic complications in HSCT patients. Simone Cesaro. Pediatric Hematology Oncology Verona, Italy. Session II: organ specific complications
Session II: organ specific complications Infective hepatic complications in HSCT patients Simone Cesaro Pediatric Hematology Oncology Verona, Italy simone.cesaro@ospedaleuniverona.it Liver complications
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More information' Ardo Abdiueli Aden, '
ORIGINAL ARTICLES Slowlv Tapering Off Steroids Protects the Graft Against Hepatiti's C Kecurrence After Liver Transplantahon ' Ardo Abdiueli Aden, ' St$uno Brillunti, * Murco fivurelli, ' Nicolu De Ruvo,
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationViral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH
Viral hepatitis Blood Born hepatitis Dr. MONA BADR Assistant Professor College of Medicine & KKUH Outline Introduction to hepatitis Characteristics of viral hepatitis Mode of transmission Markers of hepatitis
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationESCMID Online Lecture Library. by author
Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationESCCMID OLL. by Author. Hepatitis in immunocompromised hosts. Treviso, July 5, Saverio G Parisi
Hepatitis in immunocompromised hosts Treviso, July 5, 2011 Saverio G Parisi Department of Histology, Microbiology and Medical Biotechnology Università di Padova HBV Virological categories Persistent HBV
More informationLiver transplantation is the only hope for patients with terminal. Indication and Prognosis of Liver Transplantation. Abstract
Indication and Prognosis of Liver Transplantation Jae Won Joh, M.D. Department of General Surgery Sungkyunkwan University School of Medicine Samsung Medical Center E mail: jwjoh@smc.samsung.co.kr Abstract
More informationCase Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation
108 Diagnostic Problems in Hepatology Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation Brian Kim, MD 1 Anshu Trivedi, MD
More informationHistopathological Causes of Late Liver Allograft Dysfunction: Analysis at a Single Institution
The Korean Journal of Pathology 2013; 47: 21-27 ORIGINAL ARTICLE Histopathological Causes of Late Liver Allograft Dysfunction: Analysis at a Single Institution Eun Shin Ji Hoon Kim 1 Eunsil Yu 1 Department
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationCadaver Donor Screening for Infectious Agents in Solid Organ Transplantation
781 SPECIAL SECTION: INFECTIONS IN TRANSPLANTATION AND OTHER IMMUNOCOMPROMISED HOSTS David R. Snydman, Section Editor Cadaver Donor Screening for Infectious Agents in Solid Organ Transplantation Francis
More informationBSG/ACP annual course Royal College of Pathologists Infections and Inflammations of the Hepato-Biliary System Hepatitis B and D
BSG/ACP annual course Royal College of Pathologists Infections and Inflammations of the Hepato-Biliary System Hepatitis B and D Amar Paul Dhillon Royal Free & University College Medical School Thurs 10
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationHepatitis C virus (HCV)-cirrhosis is the most frequent
Contribution of Donor Age to the Recent Decrease in Patient Survival Among HCV-Infected Liver Transplant Recipients Marina Berenguer, 1 Martín Prieto, 1 Fernando San Juan, 2 José M. Rayón, 3 Fernando Martinez,
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationDevelopment of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,
More informationHepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma
Editorial Hepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma Kazunori Kawaguchi, Masao Honda, Shuichi Kaneko Department of Gastroenterology, Kanazawa University
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationLiver transplantation for HCV and HBV in The Czech Republic. Soňa Fraňková Institute for Clinical and Experimental Medicine Prague, Czech Republic
Liver transplantation for HCV and HBV in The Czech Republic Soňa Fraňková Institute for Clinical and Experimental Medicine Prague, Czech Republic Disclosures Speaking fees: Abbvie, Gilead, MSD, Novartis
More informationOccult Hepatitis B Infection: why, who and what to do?
Occult Hepatitis B Infection: why, who and what to do? MF Yuen, MD, PhD Chair of Gastroenterology and Hepatology Department of Medicine The University of Hong Kong Queen Mary Hospital, Hong Kong Who? Different
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationEduardo Barroso. Hepato-Bílio-Pancreatic and Transplantation Center Hospital Curry Cabral, Lisbon
Eduardo Barroso Hepato-Bílio-Pancreatic and Transplantation Center Hospital Curry Cabral, Lisbon % 90 85 80 75 70 65 60 55 86 83 83 82 75,3 74 74,2 72 72 68 62 60 0 2 4 6 8 10 12 Anos Busutil and Col.
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationLiver transplantation (LT) is a widely accepted
Original Article / Transplantation Hepatobiliary & Pancreatic Diseases International Comparison of hepatitis B prophylactic outcomes in living donor liver transplantation recipients who meet the Milan
More informationHBV PUBLIC HEALTH IMPLICATIONS
جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢ HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide.
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationPathological Features and Prognosis in Chronic Hepatitis B Virus Carriers
The Journal of International Medical Research 2011; 39: 71 77 Pathological Features and Prognosis in Chronic Hepatitis B Virus Carriers ZH LU, W CHEN, ZC JU, H PEI, XJ YANG, XB GU AND LH HUANG Department
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationChronic infection with hepatitis B virus (HBV) is a
Clinical Improvement in Patients With Decompensated Liver Disease Caused by Hepatitis B After Treatment With Lamivudine Craig A. Sponseller, Bruce R. Bacon, and Adrian M. Di Bisceglie Lamivudine is effective
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationChronic hepatitis B virus (HBV) infection affects
GASTROENTEROLOGY 2009;136:505 512 Predictive Factors for Early HBeAg Seroconversion in Acute Exacerbation of Patients With HBeAg-Positive Chronic Hepatitis B HYOUNG SU KIM,* HA JUNG KIM, WOON GEON SHIN,*
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationHepatitis B Virus Markers in Male Blood Donors
1 Bahrain Medical Bulletin, Vol.24, No.4, December 2002 Hepatitis B Virus Markers in Male Blood Donors Abdullah Saleh Shatoor, MD, ARBIM, FKFSH (CV)* Mubarak H Zafer, MD, FRCPA** Objective: To study the
More information